INJECTION
India to make drugs for diabetes, obesity under PLI by 2026, says report
India plans to incentivize local manufacturing of GLP-1 drugs, crucial for treating diabetes and obesity, starting in 2026, as per a government official speaking to Reuters. These drugs, originally approved for diabetes treatment, are also used for obesity due to their ability to slow digestion and reduce appetite. Novo Nordisk's patent on semaglutide, a key ingredient in popular drugs like Wegovy and Ozempic, is set to expire in India by 2026. Indian companies are already preparing to manufacture these drugs under the government's production-linked incentive (PLI) scheme.
Jubilant Pharmova's US arm prepays Rs 626 crore term loan
Jubilant Pharmova's US subsidiary secured a $75 million term loan, as of March 31, 2024, the company's gross debt stood at Rs. 3,414 crore and net debt at Rs. 2,457 crore. In FY24, the company reported revenue of Rs. 6,772 crore and a net profit of Rs. 195 crore. The net debt to Ebitda ratio improved from 2.93x to 2.48x.
Lupin, Eugia recall products from US market: USFDA
Drugmakers Lupin and Aurobindo Pharma are recalling products from the American market due to manufacturing issues, as reported by the US Food and Drug Administration (USFDA). Lupin Pharmaceuticals Inc, a US-based unit of Lupin, is specifically recalling 3,552 bottles of Cefixime for Oral Suspension (USP 200 mg/5 mL) because of "failed content uniformity specifications."
Look-alike, sounding similar drugs likely to face strict action
Earlier, in January India's Drug Technical Advisory Board (DTAB), India's apex drug advisory body, deliberated on the issue of same brand name (including look-alike and sound-alike ones) for different category of products and it suggested that to ensure patient safety, the manufacturing and marketing of different drugs with same brand name should "not be allowed."
Biocon seeks partner to test generic Wegovy, Ozempic in China
India's Biocon is seeking a Chinese partner to conduct clinical trials on generic versions of Novo Nordisk's popular diabetes drug Ozempic and weight loss treatment Wegovy. Biocon aims to eventually launch these generics globally, with plans to find a partner for the trials on over 500 patients in China, citing the substantial investment required. The move comes ahead of the patent protection expiry on key ingredients in the drugs in 2026.
Zydus to make Biotax 1g injection available with 10ml sterile water post Nepal regulator's objection
The Indian pharmaceuticals group refuted a media report that the Department of Drug Administration, Nepal has suspended sales and distribution of Biotax 1gm due to "serious health risks" stating these were "misleading and erroneous" as it complies with all quality parameters as per approved specification.
- Go To Page 1
Ozempic frenzy lures rich Indians to brave the gray market
People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage, fueling a high demand. According to Goldman Sachs Research, the anti-obesity medication market could hit $100 billion by 2030. In contrast, Indians have largely been observers in this global frenzy over the new weight-loss solutions.
Alembic Pharma gets USFDA nod for generic injection to treat hereditary angioedema
The approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) for Icatibant injection of strengths 30 mg/3 mL (10 mg/mL) single-dose prefilled syringe, Alembic Pharmaceuticals said in a regulatory filing.
Sun Pharma-Moebius Medical anti-osteoarthritis injection shows sustained pain relief in clinical trials
Sun Pharma and Moebius Medical announced that their intra-articular injection MM-II showed greater pain relief than placebo for up to 26 weeks in osteoarthritis (OA) patients, based on clinical trial data. The study demonstrated that from weeks 12 to 26, more patients on MM-II experienced significant pain improvement compared to those on placebo. MM-II, a novel non-opioid, uses a proprietary suspension of liposomes to reduce joint friction and pain. The companies plan to initiate a Phase 3 clinical program and seek a CE Mark for the product in the European Union.
Suraksha Group injects ₹125 crore to revive stalled Jaypee projects
The Suraksha Group has infused ₹125 crore into Jaypee Infratech to speed up construction, bringing hope to over 20,000 homebuyers. This investment, part of the approved resolution plan, aims to kickstart construction and ensure timely completion. The National Company Law Appellate Tribunal (NCLAT) recently approved Suraksha's plan, directing compensation of ₹1,335 crore to YEIDA over four years for the benefit of farmers. Suraksha's plan also includes appointments to the JIL board and commitments to address homebuyer concerns.
RBI using forex market tools to ease liquidity tightness
RBI uses forex tools to inject cash into banking system ahead of large outflows due to advance tax payments, keeping borrowing costs low and increasing reserves without impacting inflation-fighting stance.
Dr Reddy's signs in-licensing pact with Ingenus Pharmaceuticals for cancer treatment injection
Dr Reddy's Laboratories Ltd has signed a licensing agreement with US-based Ingenus Pharmaceuticals to commercialize Cyclophosphamide injection for cancer treatment. Dr Reddy's USA will commercialize the injection in the US market, paying Ingenus 50% of the calculated profit share.
Biosimilars offering a great opportunity in growing market: Kewal Handa
The prices have really been coming down in terms of raw materials and particularly in APIs. There is a lot of stability there. China are also now trying to align themselves to the global market requirements and they are also very keen to see that their factories start producing at the scale they were doing prior to COVID.
ChrysCapital sets sights on pharma buyout deals
ChrysCapital, led by MD Kshitij Sheth, aims to acquire Indian companies in the formulation business with potential valuations of $200 million-$500 million, focusing on growth and eventual public listings.
Chinese scientists develop cure for diabetes, insulin patient becomes medicine-free in just 3 months
Chinese scientists achieve diabetes cure through innovative cell therapy, detailed in Cell Discovery. Patient, treated in July 2021, no longer requires insulin after eleven weeks, and is now medication-free for 33 months. The breakthrough, praised by Timothy Kieffer, signifies a major advancement in diabetes treatment. This novel approach utilizes the body's regenerative abilities and could alleviate China's healthcare burden. Further studies are needed for validation.
Don’t pop that pill daily: Doctors red-flag proton pump inhibitors used to treat acid reflux, heartburns
The reason for the popularity of PPIs among doctors and patients is not tough to gauge. With unhealthy lifestyles and dietary habits, acidity is common among Indians. While many brands of PPIs are sold almost over-the-counter, Pan, Pantop, Omez and Rablet fly off the chemist’s shelves. Doctors warn that overuse of these drugs can have a slow and debilitating impact.
Liquidity deficit surges to four-month high
The shortfall of funds has pushed up the weighted average call rate (WACR), which represents banks' overnight cost of borrowing and functions as a determinant of other borrowing costs in the economy too. On Wednesday, the WACR closed at 6.75%, the same rate as the RBI's Marginal Standing Facility (MSF).
Cipla gets USFDA nod to market Lanreotide injection
Cipla has received approval from the US FDA to market its Lanreotide injection, a generic medication for treating acromegaly and other conditions. The product is a therapeutic equivalent of Somatuline Depot Injection, which had sales of around USD 898 million in the US for the 12-month period ending March 2024.
Eris Lifesciences Q4 Results: Net profit jumps over 29% to Rs 80 crore
The Ahmedabad-based drug maker reported a net profit of Rs 61.5 crore during the corresponding quarter of the previous year. Revenue of Q4FY 24 grew by 37% YoY to Rs 551 crore. The net debt on March 31 stood at Rs 2700 crore.
Serum Partners US company to advance needle-free injection technology
SII said, in a statement on Friday that the partnership with IntegriMedical aligns with its vision of 'Health for All' and IntegriMedical's mission to 'transform healthcare globally' by providing patient comfort, ensuring increased patient compliance, reducing needle-stick injuries, and enhancing the efficacy of liquid medication via needle-free dispersion.
Sugar level shot up in jail, was denied insulin injections for 15 days, claims Arvind Kejriwal at Maharashtra rally
Delhi Chief Minister Arvind Kejriwal alleged that his sugar levels rose in jail and he was denied insulin injections. Speaking at a rally in Maharashtra, he criticized the BJP and suggested that Sharad Pawar and Uddhav Thackeray might face imprisonment if the BJP comes to power. The Tihar jail administration stated that Kejriwal had stopped insulin dosage on advice from a Telangana doctor prior to his arrest. Medical reports from RML Hospital indicated that Kejriwal was not advised insulin and was prescribed oral anti-diabetic drugs.
Serum Institute buys 20% stake in IntegriMedical
Serum Institute of India acquires 20% stake in IntegriMedical for N-FIS drug delivery solution. Adar Poonawalla envisions a needle-free vaccine administration. N-FIS has regulatory approvals and patented technology. Available in the Indian private market, it eliminates needle-phobia and prevents injuries.
US President Joe Biden says Donald Trump should have injected himself with bleach
Biden mocks Trump's bleach injection idea, highlighting chaos in Trump's presidency during an election fundraiser. He hints at the upcoming 2024 election rematch and emphasizes the importance of the nation's memory.
Best AI tokens to invest in 2024: Newly emerging AI tokens
Investment manager VanEck predicts revenue from these projects could reach $10.2 billion by 2030 – and a staggering $51 billion in a best-case scenario.
FPIs take cautious approach amid ongoing general elections; inject Rs 1,156 cr in May
"With general elections in full swing in India, foreign investors have adopted a wait and watch approach, until the election results are out," Himanshu Srivastava, Associate Director - Manager Research, Morningstar Investment Research India, said.
Sanofi gets nod for injectable Polio vaccine
The announcement comes a day after ET reported that the company had ceased production of its ShanIPV vaccines in India, which may lead to a potential shortage in the country.
Aurobindo Pharma commissions four plants in Andhra Pradesh including Pen-G facility
The Rs 2,400 crore Pen-G plant is expected to start trial production in April and commercial production in a couple of months and the ramping up of the production will happen during the second quarter of the current fiscal, a senior official of the city-based drug maker had earlier said.
Lupin launches Ganirelix Acetate injection in US
Lupin Ltd has launched the Ganirelix Acetate injection, a single-dose prefilled syringe approved by the US FDA, for women undergoing fertility treatments. The injection, a generic equivalent to Organon USA LLC, is used to inhibit premature Luteinizing Hormone surges. It has an estimated annual sales of USD 87 million in the US.
Zydus launches pill for prostate cancer patients
The drug firm said the medication would cost Rs 6,995 per month, which is 50 per cent less than the currently available injectable options. "With this, the treatment for prostate cancer in India can now be made completely oral, thus helping patients lead a better quality of life," Zydus Lifesciences said in a regulatory filing.
Load More
